|
US4777127A
(en)
|
1985-09-30 |
1988-10-11 |
Labsystems Oy |
Human retrovirus-related products and methods of diagnosing and treating conditions associated with said retrovirus
|
|
GB8601597D0
(en)
|
1986-01-23 |
1986-02-26 |
Wilson R H |
Nucleotide sequences
|
|
US4946778A
(en)
|
1987-09-21 |
1990-08-07 |
Genex Corporation |
Single polypeptide chain binding molecules
|
|
US4704692A
(en)
|
1986-09-02 |
1987-11-03 |
Ladner Robert C |
Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
|
|
GB8702816D0
(en)
|
1987-02-07 |
1987-03-11 |
Al Sumidaie A M K |
Obtaining retrovirus-containing fraction
|
|
US5219740A
(en)
|
1987-02-13 |
1993-06-15 |
Fred Hutchinson Cancer Research Center |
Retroviral gene transfer into diploid fibroblasts for gene therapy
|
|
AP129A
(en)
|
1988-06-03 |
1991-04-17 |
Smithkline Biologicals S A |
Expression of retrovirus gag protein eukaryotic cells
|
|
JP2752788B2
(ja)
|
1989-01-23 |
1998-05-18 |
カイロン コーポレイション |
感染および過剰増殖障害の為の組換え療法
|
|
JP4041535B2
(ja)
|
1989-08-18 |
2008-01-30 |
オックスフォード バイオメディカ（ユーケー）リミテッド |
標的細胞にベクター構造体を運搬する組換レトロウィルス
|
|
US5585362A
(en)
|
1989-08-22 |
1996-12-17 |
The Regents Of The University Of Michigan |
Adenovirus vectors for gene therapy
|
|
US5283173A
(en)
|
1990-01-24 |
1994-02-01 |
The Research Foundation Of State University Of New York |
System to detect protein-protein interactions
|
|
US5427908A
(en)
|
1990-05-01 |
1995-06-27 |
Affymax Technologies N.V. |
Recombinant library screening methods
|
|
JP3534749B2
(ja)
|
1991-08-20 |
2004-06-07 |
アメリカ合衆国 |
アデノウイルスが介在する胃腸管への遺伝子の輸送
|
|
ES2136092T3
(es)
|
1991-09-23 |
1999-11-16 |
Medical Res Council |
Procedimientos para la produccion de anticuerpos humanizados.
|
|
WO1993010218A1
(en)
|
1991-11-14 |
1993-05-27 |
The United States Government As Represented By The Secretary Of The Department Of Health And Human Services |
Vectors including foreign genes and negative selective markers
|
|
GB9125623D0
(en)
|
1991-12-02 |
1992-01-29 |
Dynal As |
Cell modification
|
|
FR2688514A1
(fr)
|
1992-03-16 |
1993-09-17 |
Centre Nat Rech Scient |
Adenovirus recombinants defectifs exprimant des cytokines et medicaments antitumoraux les contenant.
|
|
US5733743A
(en)
|
1992-03-24 |
1998-03-31 |
Cambridge Antibody Technology Limited |
Methods for producing members of specific binding pairs
|
|
EP0650370A4
(en)
|
1992-06-08 |
1995-11-22 |
Univ California |
METHODS AND COMPOSITIONS TARGETED ON SPECIFIC TISSUES.
|
|
CA2137361A1
(en)
|
1992-06-10 |
1993-12-23 |
W. French Anderson |
Vector particles resistant to inactivation by human serum
|
|
GB2269175A
(en)
|
1992-07-31 |
1994-02-02 |
Imperial College |
Retroviral vectors
|
|
AU680459B2
(en)
|
1992-12-03 |
1997-07-31 |
Genzyme Corporation |
Gene therapy for cystic fibrosis
|
|
ES2249761T3
(es)
|
1993-06-24 |
2006-04-01 |
Advec Inc. |
Vectores de adenovirus para terapia genica.
|
|
EP0648835A1
(en)
|
1993-10-14 |
1995-04-19 |
The Procter & Gamble Company |
Use of alkaline polyammonium salts to increase cationic density in fabric softeners
|
|
EP1637608B1
(en)
|
1993-10-25 |
2009-07-22 |
CANJI, Inc. |
Recombinant adenoviral vector and methods of use
|
|
US6265150B1
(en)
|
1995-06-07 |
2001-07-24 |
Becton Dickinson & Company |
Phage antibodies
|
|
US5756910A
(en)
|
1996-08-28 |
1998-05-26 |
Burgett, Inc. |
Method and apparatus for actuating solenoids in a player piano
|
|
ES2278399T3
(es)
|
1996-11-20 |
2007-08-01 |
Introgen Therapeutics, Inc. |
Metodo mejorado para la produccion y purificacion de vectores adenovirales.
|
|
EP1914242A1
(en)
|
2006-10-19 |
2008-04-23 |
Sanofi-Aventis |
Novel anti-CD38 antibodies for the treatment of cancer
|
|
RU2476441C2
(ru)
|
2007-10-19 |
2013-02-27 |
Сиэтл Дженетикс, Инк. |
Cd19-связывающие средства и их применение
|
|
CH704227B1
(fr)
|
2009-10-19 |
2015-05-15 |
Tristem Trading Cyprus Ltd |
Procédé pour obtenir des cellules cibles reprogrammées.
|
|
DK2580243T3
(da)
|
2010-06-09 |
2020-01-13 |
Genmab As |
Antibodies against human cd38
|
|
CA2993567C
(en)
|
2010-07-21 |
2022-06-28 |
Sangamo Biosciences, Inc. |
Methods and compositions for modification of a t-cell receptor gene
|
|
PH12013501201A1
(en)
|
2010-12-09 |
2013-07-29 |
Univ Pennsylvania |
Use of chimeric antigen receptor-modified t cells to treat cancer
|
|
US9409950B2
(en)
|
2010-12-23 |
2016-08-09 |
Biogen Ma Inc. |
Linker peptides and polypeptides comprising same
|
|
US20130309223A1
(en)
|
2012-05-18 |
2013-11-21 |
Seattle Genetics, Inc. |
CD33 Antibodies And Use Of Same To Treat Cancer
|
|
EP3241902B1
(en)
|
2012-05-25 |
2018-02-28 |
The Regents of The University of California |
Methods and compositions for rna-directed target dna modification and for rna-directed modulation of transcription
|
|
US8697359B1
(en)
|
2012-12-12 |
2014-04-15 |
The Broad Institute, Inc. |
CRISPR-Cas systems and methods for altering expression of gene products
|
|
WO2014093694A1
(en)
|
2012-12-12 |
2014-06-19 |
The Broad Institute, Inc. |
Crispr-cas nickase systems, methods and compositions for sequence manipulation in eukaryotes
|
|
WO2014191128A1
(en)
|
2013-05-29 |
2014-12-04 |
Cellectis |
Methods for engineering t cells for immunotherapy by using rna-guided cas nuclease system
|
|
CA2920368C
(en)
|
2013-07-23 |
2023-03-21 |
Centro De Inmunologia Molecular |
Use of a cd6 binding partner and method based thereon
|
|
EP2833591A1
(en)
|
2013-07-31 |
2015-02-04 |
Siemens Aktiengesellschaft |
Subsea data communication interface unit
|
|
US10287354B2
(en)
|
2013-12-20 |
2019-05-14 |
Novartis Ag |
Regulatable chimeric antigen receptor
|
|
ES3063961T3
(en)
|
2014-02-14 |
2026-04-21 |
Cellectis |
Cells for immunotherapy engineered for targeting antigen present both on immune cells and pathological cells
|
|
CA2943008C
(en)
|
2014-03-19 |
2021-03-30 |
Cellectis |
Cd123 specific chimeric antigen receptors for cancer immunotherapy
|
|
EP3126390B2
(en)
|
2014-04-03 |
2026-01-07 |
Cellectis |
Cd33 specific chimeric antigen receptors for cancer immunotherapy
|
|
EP3556858A3
(en)
|
2014-04-09 |
2020-01-22 |
Editas Medicine, Inc. |
Crispr/cas-related methods and compositions for treating cystic fibrosis
|
|
EP3134515B1
(en)
|
2014-04-24 |
2019-03-27 |
Board of Regents, The University of Texas System |
Application of induced pluripotent stem cells to generate adoptive cell therapy products
|
|
WO2015195547A1
(en)
|
2014-06-16 |
2015-12-23 |
University Of Washington |
Methods for controlling stem cell potential and for gene editing in stem cells
|
|
US9212225B1
(en)
|
2014-07-01 |
2015-12-15 |
Amphivena Therapeutics, Inc. |
Bispecific CD33 and CD3 binding proteins
|
|
SG10201913765YA
(en)
|
2014-07-21 |
2020-03-30 |
Novartis Ag |
Treatment of cancer using a cd33 chimeric antigen receptor
|
|
KR20170037625A
(ko)
|
2014-07-21 |
2017-04-04 |
노파르티스 아게 |
Cll-1 키메라 항원 수용체를 사용한 암의 치료
|
|
HUE055583T2
(hu)
|
2014-09-16 |
2021-12-28 |
Sangamo Therapeutics Inc |
Eljárások és készítmények nukleáz által közvetített genommódosításhoz és -javításhoz hematopoetikus õssejtekben
|
|
KR101799975B1
(ko)
|
2014-10-31 |
2017-11-21 |
에스케이씨하이테크앤마케팅(유) |
액정표시장치용 색순도 향상 및 휘도 보상 필름 및 이를 포함하는 액정표시장치
|
|
US10201606B2
(en)
|
2014-11-26 |
2019-02-12 |
Miltenyi Biotec Gmbh |
Combination immunotherapy of antigen-recognizing receptors and hematopoietic cells for the treatment of diseases
|
|
US10900034B2
(en)
|
2014-12-03 |
2021-01-26 |
Agilent Technologies, Inc. |
Guide RNA with chemical modifications
|
|
AU2015358615B2
(en)
|
2014-12-04 |
2021-08-05 |
Janssen Biotech, Inc. |
Anti-CD38 antibodies for treatment of acute myeloid leukemia
|
|
WO2016115482A1
(en)
|
2015-01-16 |
2016-07-21 |
Novartis Pharma Ag |
Phosphoglycerate kinase 1 (pgk) promoters and methods of use for expressing chimeric antigen receptor
|
|
ES2869972T3
(es)
|
2015-01-26 |
2021-10-26 |
Cellectis |
Sistemas de receptores de antígenos quiméricos dirigidos por mAb para clasificar/agotar células inmunitarias genomanipuladas
|
|
EP3280803B1
(en)
*
|
2015-04-06 |
2021-05-26 |
The Board of Trustees of the Leland Stanford Junior University |
Chemically modified guide rnas for crispr/cas-mediated gene regulation
|
|
MX2017012939A
(es)
*
|
2015-04-08 |
2018-05-22 |
Novartis Ag |
Terapias cd20, terapias cd22 y terapias de combinacion con una celula que expresa un receptor quimerico de antigeno (car) de cd19.
|
|
RU2749113C2
(ru)
|
2015-04-22 |
2021-06-04 |
Куревак Аг |
Содержащая рнк композиция для лечения опухолевых заболеваний
|
|
GB201507119D0
(en)
|
2015-04-27 |
2015-06-10 |
Ucl Business Plc |
Nucleic Acid Construct
|
|
WO2016176651A2
(en)
|
2015-04-29 |
2016-11-03 |
Fred Hutchinson Cancer Research Center |
Modified hematopoietic stem/progenitor and non-t effector cells, and uses thereof
|
|
AU2016261358B2
(en)
|
2015-05-11 |
2021-09-16 |
Editas Medicine, Inc. |
Optimized CRISPR/Cas9 systems and methods for gene editing in stem cells
|
|
EP3307887A1
(en)
|
2015-06-09 |
2018-04-18 |
Editas Medicine, Inc. |
Crispr/cas-related methods and compositions for improving transplantation
|
|
EP3310378B1
(en)
|
2015-06-16 |
2024-01-24 |
F. Hoffmann-La Roche AG |
Anti-cll-1 antibodies and methods of use
|
|
CA2994746A1
(en)
|
2015-08-11 |
2017-02-16 |
Cellectis |
Cells for immunotherapy engineered for targeting cd38 antigen and for cd38 gene inactivation
|
|
CN108290939B
(zh)
|
2015-10-16 |
2023-01-13 |
纽约市哥伦比亚大学理事会 |
用于抑制谱系特异性抗原的组合物和方法
|
|
JP7109784B2
(ja)
|
2015-10-23 |
2022-08-01 |
プレジデント アンド フェローズ オブ ハーバード カレッジ |
遺伝子編集のための進化したＣａｓ９蛋白質
|
|
MY185961A
(en)
|
2015-11-04 |
2021-06-14 |
Univ Pennsylvania |
Methods and compositions for gene editing in hematopoietic stem cells
|
|
CN108290955A
(zh)
|
2015-11-24 |
2018-07-17 |
塞勒兰特治疗公司 |
人源化抗-cll-1抗体
|
|
WO2017172981A2
(en)
|
2016-03-29 |
2017-10-05 |
University Of Southern California |
Chimeric antigen receptors targeting cancer
|
|
US11499168B2
(en)
|
2016-04-25 |
2022-11-15 |
Universitat Basel |
Allele editing and applications thereof
|
|
US10767175B2
(en)
|
2016-06-08 |
2020-09-08 |
Agilent Technologies, Inc. |
High specificity genome editing using chemically modified guide RNAs
|
|
SG11201810640RA
(en)
|
2016-06-08 |
2018-12-28 |
Intrexon Corp |
Cd33 specific chimeric antigen receptors
|
|
JP7114490B2
(ja)
|
2016-06-24 |
2022-08-08 |
アイセル・ジーン・セラピューティクス・エルエルシー |
キメラ抗体受容体（ＣＡＲｓ）の構成およびその使用方法
|
|
JP7195154B2
(ja)
|
2016-07-06 |
2022-12-23 |
セレクティス |
初代免疫細胞における逐次遺伝子編集
|
|
ES2883678T3
(es)
|
2016-10-21 |
2021-12-09 |
Inst Nat Sante Rech Med |
Métodos para promover la respuesta de linfocitos T
|
|
AU2017355218B2
(en)
|
2016-11-02 |
2024-02-22 |
Universität Basel |
Immunologically discernible cell surface variants for use in cell therapy
|
|
AU2017388753A1
(en)
|
2016-12-30 |
2019-07-11 |
Editas Medicine, Inc. |
Synthetic guide molecules, compositions and methods relating thereto
|
|
SG11201907870VA
(en)
|
2017-02-28 |
2019-09-27 |
Vor Biopharma Inc |
Compositions and methods for inhibition of lineage specific proteins
|
|
JP2020510439A
(ja)
|
2017-03-10 |
2020-04-09 |
プレジデント アンド フェローズ オブ ハーバード カレッジ |
シトシンからグアニンへの塩基編集因子
|
|
CA3057192A1
(en)
|
2017-03-23 |
2018-09-27 |
President And Fellows Of Harvard College |
Nucleobase editors comprising nucleic acid programmable dna binding proteins
|
|
KR20190140943A
(ko)
|
2017-04-24 |
2019-12-20 |
메모리얼 슬로안 케터링 캔서 센터 |
항-cd33 항체 제제
|
|
US10780119B2
(en)
|
2017-05-24 |
2020-09-22 |
Effector Therapeutics Inc. |
Methods and compositions for cellular immunotherapy
|
|
US11718659B2
(en)
|
2017-08-28 |
2023-08-08 |
The Trustees Of Columbia University In The City Of New York |
CD33 exon 2 deficient donor stem cells for use with CD33 targeting agents
|
|
AU2019214935B2
(en)
|
2018-01-30 |
2025-06-26 |
Editas Medicine, Inc. |
Systems and methods for modulating chromosomal rearrangements
|
|
WO2019157326A1
(en)
|
2018-02-08 |
2019-08-15 |
Zymergen Inc. |
Genome editing using crispr in corynebacterium
|
|
TWI669677B
(zh)
|
2018-03-07 |
2019-08-21 |
光陽工業股份有限公司 |
充電座管理方法、用於充電座管理方法的伺服器及充電座
|
|
JP7575271B2
(ja)
|
2018-03-29 |
2024-10-29 |
フェイト セラピューティクス，インコーポレイテッド |
操作された免疫エフェクター細胞およびその使用
|
|
WO2020028533A1
(en)
|
2018-08-01 |
2020-02-06 |
Yale University |
Compositions and methods for identification of membrane targets for enhancement of t cell activity against cancer
|
|
CA3110837A1
(en)
|
2018-08-28 |
2020-03-05 |
Vor Biopharma Inc. |
Genetically engineered hematopoietic stem cells and uses thereof
|
|
SG11202103832SA
(en)
*
|
2018-11-07 |
2021-05-28 |
Crispr Therapeutics Ag |
Anti-cd33 immune cell cancer therapy
|
|
US20220133790A1
(en)
|
2019-01-16 |
2022-05-05 |
Beam Therapeutics Inc. |
Modified immune cells having enhanced anti-neoplasia activity and immunosuppression resistance
|
|
MX2021008490A
(es)
|
2019-01-16 |
2021-09-28 |
Univ Columbia |
Composiciones y metodos para la inhibicion de antigenos con especificidad de linaje.
|
|
WO2020168122A1
(en)
|
2019-02-13 |
2020-08-20 |
Beam Therapeutics Inc. |
Modified immune cells having adenosine deaminase base editors for modifying a nucleobase in a target sequence
|
|
CN114423865A
(zh)
*
|
2019-05-23 |
2022-04-29 |
Vor生物制药股份有限公司 |
Cd33修饰的组合物和方法
|
|
EA202191979A1
(ru)
|
2019-05-24 |
2021-11-01 |
Зе Трастис Оф Коламбия Юниверсити Ин Зе Сити Оф Нью-Йорк |
Композиции и способы ингибирования линиеспецифических антигенов
|
|
CA3144356A1
(en)
|
2019-06-21 |
2020-12-24 |
Function Oncology, Inc. |
A genetic pharmacopeia for comprehensive functional profiling of human cancers
|
|
AU2020336211A1
(en)
|
2019-08-28 |
2022-03-10 |
Vor Biopharma Inc. |
Compositions and methods for CD123 modification
|
|
US20220290160A1
(en)
|
2019-08-28 |
2022-09-15 |
Vor Biopharma Inc. |
Compositions and methods for cll1 modification
|
|
US20240110189A1
(en)
|
2020-08-28 |
2024-04-04 |
Vor Biopharma Inc. |
Compositions and methods for cll1 modification
|
|
JP2023541457A
(ja)
|
2020-09-14 |
2023-10-02 |
ブイオーアール バイオファーマ インコーポレーテッド |
Ｃｄ３８修飾のための化合物および方法
|
|
WO2022067240A1
(en)
|
2020-09-28 |
2022-03-31 |
Vor Biopharma, Inc. |
Compositions and methods for cd6 modification
|
|
WO2022147347A1
(en)
*
|
2020-12-31 |
2022-07-07 |
Vor Biopharma Inc. |
Compositions and methods for cd34 gene modification
|
|
CA3232593A1
(en)
*
|
2021-09-14 |
2023-03-23 |
Vor Biopharma Inc. |
Compositions and methods for multiplex base editing in hematopoietic cells
|
|
US20250041339A1
(en)
|
2021-11-19 |
2025-02-06 |
The Trustees Of The University Of Pennsylvania |
Engineered Pan-Leukocyte Antigen CD45 to Facilityate CAR T Cell Therapy
|
|
WO2023118608A1
(en)
|
2021-12-23 |
2023-06-29 |
Universität Basel |
Discernible cell surface protein variants of cd45 for use in cell therapy
|
|
US20250170182A1
(en)
|
2022-02-18 |
2025-05-29 |
Dana-Farber Cancer Institute, Inc. |
Epitope engineering of cell-surface receptors
|